Expression of SMAD2/3/4 is increased in i3 cancers (Extended Data Fig. 7e) but gene signatures related to TGF-beta activity1,33–37 were not consistently different in i3 and i2 tumor cells (Supplementary Fig. 11). This evidence concerns the gene SMAD2 and neoplasm.